APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival - Seite 2
APR’s approach was shaped by its ambition of creating a product that can respond to the needs of PKU patients and resulted in the creation of the PKU GOLIKE line, a Food for Special Medical Purposes. APR's experience in identifying and applying pharmaceutical technologies to improve the efficacy and tolerability of molecules for common pathologies served as basis for improving the absorption of amino acid and allowing better metabolic management.
As part of its participation in the festival, APR attended events in Berlin (Il Kino), Rome (la Casa del Cinema) and Milan (Niguarda hospital). The festival earned the support of many rare disease associations such as:
- Eurordis - Rare Disease Europe
- ACHSE Allianz Chronischer Seltener Erkrankungen
- Uniamo - Federazione Italiana Malattie Rare
About PKU GOLIKE
PKU GOLIKE is a phenylalanine-free food intended for the dietary management of phenylketonuria (“PKU”). The product is comprised of a mixture of amino acids in the form of granules and is available
in convenient packets and medical food bars. Engineered with the Relief’s patented Physiomimic Technology platform, PKU GOLIKE is the first prolonged-release amino acid product, characterized by a
special coating that ensures physiological absorption of the amino acids mirroring that of natural proteins. In addition, the special coating masks the unpleasant taste, odor, and aftertaste of the
amino acids. PKU GOLIKE has been commercially available in the E.U. since 2019 and was launched in the U.S. in October 2022.
Lesen Sie auch
About Relief
Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare
and ultra-rare diseases including metabolic disorders, pulmonary diseases, and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively
address significant unmet medical needs, including PKU GOLIKE, engineered with the proprietary physiomimic technology, which is the first prolonged-release amino acid product commercialized for the
dietary management of phenylketonuria (“PKU”). Relief has a collaboration and license agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium
phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (“MSUD”). Relief also continues to develop aviptadil
for several rare pulmonary indications. Further, Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of
epidermolysis bullosa (“EB”), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the U.S. Food & Drug Administration.
Relief is commercializing several legacy products via licensing and distribution partners.